STRATA Skin Sciences Validated Again for Its Personalized Method as New Study Showcases XTRAC® Excimer Laser Treatment with Topical Drug for Psoriasis
Study Publication: STRATA Skin Sciences announced a peer-reviewed study published in Lasers in Medical Science, demonstrating that combining the XTRAC 308nm Excimer Laser with 0.1% tacrolimus ointment significantly improves treatment outcomes for plaque-type psoriasis compared to using tacrolimus alone.
Clinical Findings: The study involved 100 patients and showed a statistically significant reduction in psoriasis severity (PASI scores) for those receiving combination therapy, with no serious adverse events reported, highlighting the safety and efficacy of personalized treatment approaches.
Personalized Medicine Approach: The study emphasized the importance of individualized treatment, using patient-specific dosing based on Minimum Erythema Dose (MED) to maximize therapeutic benefits while minimizing damage to healthy skin.
Strategic Implications: STRATA's findings support the use of Excimer laser therapy in conjunction with other treatments, reinforcing the company's position in personalized dermatologic care and potentially influencing reimbursement strategies as demand for non-biologic treatments grows.
Trade with 70% Backtested Accuracy
Analyst Views on SSKN
About SSKN
About the author
STRATA Showcases New Technologies at 2025 Dermatology Congress, Anticipates 12 New Clients in Mexico
- Technology Showcase: At the 2025 Ibero-Latin American Dermatology Congress, STRATA presented its XTRAC® laser and TheraclearX® acne therapy system, garnering significant interest from dermatologists and reinforcing the company's leadership in dermatological technologies.
- Market Expansion: STRATA anticipates over 12 new recurring TheraclearX® accounts in Mexico by the end of 2025, reflecting growing acceptance of non-drug treatment options among dermatologists in the region, which will drive sustainable revenue growth for the company.
- Clinical Feedback: At the congress, the first TheraClearX® user in Mexico shared her successful experience in treating mild to moderate acne, highlighting the technology's potential for significant patient improvement in a short session, which could enhance adoption rates.
- Strategic Outlook: STRATA is committed to expanding access to advanced dermatology solutions across Latin America, engaging with key opinion leaders to enhance market penetration and drive revenue growth through device-based therapies.
Teradyne Shares Surge Over 20%; Check Out 20 Stocks Making Moves in Premarket Trading
Teradyne's Strong Performance: Teradyne Inc. shares surged 20.7% in pre-market trading after reporting third-quarter earnings of 85 cents per share, exceeding analyst expectations of 79 cents, along with sales of $769.210 million, surpassing the $743.776 million estimate.
Notable Gainers: Several stocks saw significant pre-market gains, including Profusa Inc. (+72.8%), Founder Group Ltd (+59.4%), and Vsee Health Inc. (+44.3%), driven by positive developments such as manufacturing capacity increases and regulatory approvals.
Major Losers: Stride Inc. experienced a sharp decline of 36.4% after providing disappointing sales guidance, while Varonis Systems Inc. and Akebia Therapeutics Inc. also fell significantly due to lower-than-expected revenue and trial design issues, respectively.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with notable movements in both directions, reflecting investor reactions to earnings reports and company announcements.
STRATA Skin Sciences Sees 25% Pre-Market Increase — Find Out the Reasons
Stock Performance: STRATA Skin Sciences Inc. (SSKN) saw a 24.87% increase in premarket trading to $2.41 after receiving Mexican regulatory approval for its TheraClearX acne treatment system, following a previous 14.88% rise to $1.93 in regular trading.
Regulatory Approval: The Mexican health regulator COFEPRIS granted Device Registration No. 3187E2024SSA for TheraClearX, allowing it to be marketed and used in clinical settings across Mexico until November 2029.
Commercial Rollout: STRATA has initiated a commercial rollout of TheraClearX in partnership with MINO Labs, enabling physicians to use the system under a usage-based model without upfront costs.
Market Opportunity: The professional acne medication segment in Mexico is expected to nearly double by 2030, with a projected CAGR of 10.2%, highlighting significant growth potential for STRATA in the dermatology market.
Eczema Awareness Month: Clinical Research Confirms Strata Skin Sciences' XTRAC® Excimer Laser as a Revolutionary Treatment for Localized Atopic Dermatitis
Eczema Awareness Month: STRATA Skin Sciences highlights the effectiveness of the XTRAC® Excimer Laser for treating localized atopic dermatitis, as the American Medical Association expands its indications, allowing for broader reimbursement options.
Clinical Evidence and Impact: Numerous studies demonstrate the excimer laser's safety and efficacy, showing significant improvements in patients with atopic dermatitis, including reduced symptoms and long-lasting remission, particularly in difficult-to-treat areas like hands and feet.
STRATA Skin Sciences Validated Again for Its Personalized Method as New Study Showcases XTRAC® Excimer Laser Treatment with Topical Drug for Psoriasis
Study Publication: STRATA Skin Sciences announced a peer-reviewed study published in Lasers in Medical Science, demonstrating that combining the XTRAC 308nm Excimer Laser with 0.1% tacrolimus ointment significantly improves treatment outcomes for plaque-type psoriasis compared to using tacrolimus alone.
Clinical Findings: The study involved 100 patients and showed a statistically significant reduction in psoriasis severity (PASI scores) for those receiving combination therapy, with no serious adverse events reported, highlighting the safety and efficacy of personalized treatment approaches.
Personalized Medicine Approach: The study emphasized the importance of individualized treatment, using patient-specific dosing based on Minimum Erythema Dose (MED) to maximize therapeutic benefits while minimizing damage to healthy skin.
Strategic Implications: STRATA's findings support the use of Excimer laser therapy in conjunction with other treatments, reinforcing the company's position in personalized dermatologic care and potentially influencing reimbursement strategies as demand for non-biologic treatments grows.
3 Penny Stocks to Keep an Eye On as of September 25, 2025
Penny Stocks to Watch: Datavault AI, Strata Skin Sciences, and Soluna Holdings are highlighted as top penny stocks to monitor on September 25, 2025, based on their high Dollar Volume and recent market activity.
Company Highlights: Datavault AI focuses on AI-driven data solutions and recently partnered to enhance XRP adoption; Strata Skin Sciences reported promising results for a vitiligo treatment; Soluna Holdings has seen significant stock growth following a $100 million credit facility announcement.
STRATA Showcases New Technologies at 2025 Dermatology Congress, Anticipates 12 New Clients in Mexico
- Technology Showcase: At the 2025 Ibero-Latin American Dermatology Congress, STRATA presented its XTRAC® laser and TheraclearX® acne therapy system, garnering significant interest from dermatologists and reinforcing the company's leadership in dermatological technologies.
- Market Expansion: STRATA anticipates over 12 new recurring TheraclearX® accounts in Mexico by the end of 2025, reflecting growing acceptance of non-drug treatment options among dermatologists in the region, which will drive sustainable revenue growth for the company.
- Clinical Feedback: At the congress, the first TheraClearX® user in Mexico shared her successful experience in treating mild to moderate acne, highlighting the technology's potential for significant patient improvement in a short session, which could enhance adoption rates.
- Strategic Outlook: STRATA is committed to expanding access to advanced dermatology solutions across Latin America, engaging with key opinion leaders to enhance market penetration and drive revenue growth through device-based therapies.
Teradyne Shares Surge Over 20%; Check Out 20 Stocks Making Moves in Premarket Trading
Teradyne's Strong Performance: Teradyne Inc. shares surged 20.7% in pre-market trading after reporting third-quarter earnings of 85 cents per share, exceeding analyst expectations of 79 cents, along with sales of $769.210 million, surpassing the $743.776 million estimate.
Notable Gainers: Several stocks saw significant pre-market gains, including Profusa Inc. (+72.8%), Founder Group Ltd (+59.4%), and Vsee Health Inc. (+44.3%), driven by positive developments such as manufacturing capacity increases and regulatory approvals.
Major Losers: Stride Inc. experienced a sharp decline of 36.4% after providing disappointing sales guidance, while Varonis Systems Inc. and Akebia Therapeutics Inc. also fell significantly due to lower-than-expected revenue and trial design issues, respectively.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with notable movements in both directions, reflecting investor reactions to earnings reports and company announcements.
STRATA Skin Sciences Sees 25% Pre-Market Increase — Find Out the Reasons
Stock Performance: STRATA Skin Sciences Inc. (SSKN) saw a 24.87% increase in premarket trading to $2.41 after receiving Mexican regulatory approval for its TheraClearX acne treatment system, following a previous 14.88% rise to $1.93 in regular trading.
Regulatory Approval: The Mexican health regulator COFEPRIS granted Device Registration No. 3187E2024SSA for TheraClearX, allowing it to be marketed and used in clinical settings across Mexico until November 2029.
Commercial Rollout: STRATA has initiated a commercial rollout of TheraClearX in partnership with MINO Labs, enabling physicians to use the system under a usage-based model without upfront costs.
Market Opportunity: The professional acne medication segment in Mexico is expected to nearly double by 2030, with a projected CAGR of 10.2%, highlighting significant growth potential for STRATA in the dermatology market.
Eczema Awareness Month: Clinical Research Confirms Strata Skin Sciences' XTRAC® Excimer Laser as a Revolutionary Treatment for Localized Atopic Dermatitis
Eczema Awareness Month: STRATA Skin Sciences highlights the effectiveness of the XTRAC® Excimer Laser for treating localized atopic dermatitis, as the American Medical Association expands its indications, allowing for broader reimbursement options.
Clinical Evidence and Impact: Numerous studies demonstrate the excimer laser's safety and efficacy, showing significant improvements in patients with atopic dermatitis, including reduced symptoms and long-lasting remission, particularly in difficult-to-treat areas like hands and feet.
STRATA Skin Sciences Validated Again for Its Personalized Method as New Study Showcases XTRAC® Excimer Laser Treatment with Topical Drug for Psoriasis
Study Publication: STRATA Skin Sciences announced a peer-reviewed study published in Lasers in Medical Science, demonstrating that combining the XTRAC 308nm Excimer Laser with 0.1% tacrolimus ointment significantly improves treatment outcomes for plaque-type psoriasis compared to using tacrolimus alone.
Clinical Findings: The study involved 100 patients and showed a statistically significant reduction in psoriasis severity (PASI scores) for those receiving combination therapy, with no serious adverse events reported, highlighting the safety and efficacy of personalized treatment approaches.
Personalized Medicine Approach: The study emphasized the importance of individualized treatment, using patient-specific dosing based on Minimum Erythema Dose (MED) to maximize therapeutic benefits while minimizing damage to healthy skin.
Strategic Implications: STRATA's findings support the use of Excimer laser therapy in conjunction with other treatments, reinforcing the company's position in personalized dermatologic care and potentially influencing reimbursement strategies as demand for non-biologic treatments grows.
3 Penny Stocks to Keep an Eye On as of September 25, 2025
Penny Stocks to Watch: Datavault AI, Strata Skin Sciences, and Soluna Holdings are highlighted as top penny stocks to monitor on September 25, 2025, based on their high Dollar Volume and recent market activity.
Company Highlights: Datavault AI focuses on AI-driven data solutions and recently partnered to enhance XRP adoption; Strata Skin Sciences reported promising results for a vitiligo treatment; Soluna Holdings has seen significant stock growth following a $100 million credit facility announcement.
